CLICK
HERE TO LAUNCH POST EASL 2008
CME PROGRAM SLIDE KIT
INTENDED
AUDIENCE
LEARNING OBJECTIVES
ACCREDITATION
AND DESIGNATION STATEMENTS
RUSH DISCLOSURE POLICY
CME
POST-TEST
 INTENDED
AUDIENCE
This program will be of interest to primary care providers and infectious disease
specialists who provide care to patients with hepatitis B.
LEARNING
OBJECTIVES
Upon
the completion of this CME activity, the participant should be able to:
•
Discuss significant developments in the diagnosis and management of hepatitis
B
• Summarize new drugs and treatment strategies for hepatitis B
•
Describe recent hepatitis therapy toxicity, drug interaction and side effect data
and strategies for management
• Identify new therapeutic strategies
to avoid or overcome antiviral resistance
• Highlight diagnosis and
management approaches for hepatitis B in individuals co-infected with HIV
ACCREDITATION
AND DESIGNATION STATEMENTS PHYSICIANS
Rush University Medical Center is accredited by the Accreditation Council for
Continuing Medical Education to provide continuing medical education for physicians.
Rush University Medical Center designates this educational activity for a maximum
of 1 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit
commensurate with the extent of their participation in the activity.
Release
Date: April 2008. The opinions or views expressed in this educational program
are those of the participants and do not necessarily reflect the opinions or recommendations
of Gilead Sciences or Rush University Medical Center. Produced in accordance with
all ACCME Essential Areas and Elements and Accreditation Policies. Expected time
of completion 1 hour. The faculty may have included discussion on unlabeled uses
of a commercial product or an investigational use of a product not yet approved
for this purpose. Please consult the full prescribing information before using
any medication mentioned in this educational program. Expiration Date: March
31, 2009.
RUSH
DISCLOSURE POLICY
It
is the policy of the Rush University Medical Center Office of Continuing Medical
Education to ensure that its CME activities are independent, free of commercial
bias and beyond the control of persons or organizations with an economic interest
in influencing the content of CME. Everyone who is in a position to control the
content of an educational activity must disclose all relevant financial relationshipswith
any commercial interest (including but not limited to pharmaceutical companies,
biomedical device manufacturers, or other corporations whose products or services
are related to the subject matter of the presentation topic) within the preceding
12 months. If there are relationships that create a conflict of interest, these
must be resolved by the CME Course Director in consultation with the Office of
Continuing Medical Education prior to the participation of the faculty member
in the development or presentation of course content.
| 
